Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

NCT06963281 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: IBI3020

Sponsor

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Collaborators

[object Object]